Skip to search formSkip to main contentSkip to account menu

MGCD516

Known as: Multitargeted Kinase Inhibitor MGCD516 
An orally bioavailable, receptor tyrosine kinase (RTK) inhibitor with potential antineoplastic activity. Upon administration, multitargeted kinase… 
National Institutes of Health

Related topics

Related topics

3 relations
NCIt Antineoplastic Agent TerminologyReceptor Tyrosine Kinase Inhibition

Broader (1)

sitravatinib

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
Pd(ii)-Complexes of a novel pyridinone based tripeptide conjugate: solution and solid state studies.
A novel peptide conjugate (H(L2)) incorporating N-donors of the peptide backbone and an (O,O) donor set of a hydroxypyridinone… 
2019
2019
Abstract 2740: MET exon 14 skipping mutation promotes metastasis via activation of the PI3K/Akt-Rac1 pathway in non-small cell lung cancer
The MET proto-oncogene plays crucial roles in cell growth and proliferation, epithelial-mesenchymal (EMT) transition, invasion… 
2018
2018
Evaluation of the spectrum selective RTK inhibitor sitravatinib in clear cell renal cell carcinoma (ccRCC) refractory to anti-angiogenic therapy (AAT).
4568Background: Sitravatinib (MGCD516) is an oral, potent small molecule inhibitor of a closely related spectrum of receptor… 
2017
2017
Poster SessionP2.06-001 A Study of MGCD516, a Receptor Tyrosine Kinase (RTK) Inhibitor, in Molecularly Selected Patients with NSCLC or Other Advanced Solid Tumors: Topic: Phase I Trials
2015
2015
A first in human phase I study of receptor tyrosine kinase (RTK) inhibitor MGCD516 in patients with advanced solid tumors.
2575Background: MGCD516 is an oral, potent small molecule inhibitor of a closely related spectrum of RTKs including RET, TRK… 
Review
2012
Review
2012
[Management of sunitinib-associated adverse events].
Patients diagnosed with metastatic renal cell carcinoma (mRCC) are currently treated with oral tyrosine kinase inhibitors (TKIs… 
2012
2012
308 DETECTION OF FUNCTIONAL CHANGES IN RENAL CELL CARCINOMA WITH POSITRON EMISSION TOMOGRAPHY
2008
2008
MDCT-Evaluation des Therapieansprechens bei Nierenzellkarzinom-Patienten unter Therapie mit „Multitargeted“ Thyrosinkynase-Inhibitoren: gelten die RECIST-Kriterien noch?
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)